Health and Healthcare
Onyx Pharma Rejects Amgen, but Will Start Search for a Buyer
Published:
Last Updated:
Onyx said that the offer “significantly undervalued” the company and its future prospects, and “was not in the best interests” of shareholders. According to a report in The Wall Street Journal, the total value of Amgen’s offer was around $10 billion, including convertible notes and options.
This morning, Onyx and Bayer HealthCare announced that the companies had submitted a new thyroid-cancer drug application to the U.S. Food and Drug Administration (FDA) and an application to market the drug in Europe. The drug already is approved for treating liver cancer and if Onyx’s application to the FDA to use the drug to treat thyroid cancer is approved, it would mark the first new treatment for thyroid cancer in 40 years.
Onyx, with a market cap of around $6.5 billion before Amgen’s offer, would benefit from a tie-up with a larger company with more experience and more sales staff to market a new drug. Amgen, with a market cap of around $74 billion, is such a company. Onyx gets the point, and sees the Amgen offer as a good place to start the bidding. It is nothing personal, just business.
Investors appear to agree. In premarket trading this morning Onyx shares are trading up more than 50% at $132.30. The stock’s 52-week range is $63.00 to $101.57.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
